Rx Medicare

EFPIA is aware and concerned by the current outbreak of a novel influenza, which appears to have originated in Mexico. We note the WHO’s decision to raise the level of influenza pandemic alert from the current phase 4 to phase 5. We will continue to monitor the situation closely, working with our colleagues at the International Federation of Pharmaceutical manufacturers and Associations.

Read More…

Related Posts

• Diagnostic Hybrids Receives FDA Emergency Use Authorization For D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
• FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
• Meridian Granted Special 510(k) Clearance To Add 2009 H1N1 Influenza A Virus Analytical Sensitivity Claim To The TRU FLU(R) Test Package Insert
• Novel H1N1 Influenza Is Widespread In Alabama; Health Care System Is Handling It Well
• Second Alabama Child Dies From Novel H1N1 Influenza
• Warnex Launches Test For Influenza A H1N1 Virus Mutation Associated With Resistance To Tamiflu(R)
• Novel H1N1 Influenza A (Swine Flu) Update For Arkansans
• Cases Of The 2009 H1N1 Influenza A Virus Confirmed In Crawford And Miami Counties
• The Immune Response To Influenza Virus Isn’t ‘All Good’
• First Novel H1N1 Influenza Cases Confirmed In Baldwin, Colbert And Dale Counties
• USC Researchers Uncover Mechanism That Allows Influenza Virus To Evade The Body¹s Immune Response
• HHS Takes Additional Steps Toward Development Of Vaccine For The Novel Influenza A (H1N1)
• First Cases Of Novel H1N1 Influenza Identified In Etowah And Mobile Counties
• H1N1 Influenza
• WHO Recommends H1N1 Be Added To Next Year’s Seasonal Flu Virus

Tags: efficacy, efpia, h1n1, influenza, novel, response, virus

This entry was posted on Wednesday, May 6th, 2009 at 1:05 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.